Benjamin Hornigold Limited Overview
Benjamin Hornigold Ltd is a Sydney-based, internally governed micro-cap listed investment company. It runs an opportunistic, absolute-return mandate across ASX-listed securities and selected listed or unlisted funds. It was floated in 2017 under external management by John Bridgeman Ltd (JBL). That relationship ended in governance failure: related-party payments, loans to JBL-group entities, a 2018 ASX suspension, an attempted takeover by JBL blocked by the Takeovers Panel, and later ASIC criminal charges against the former CEO and CFO. Since June 2019 an entirely new three-person board, chaired by small-cap fund manager Michael Glennon, has managed the portfolio itself. It uses four stated strategies: discount capture on LICs trading below NTA, merger arbitrage, deep value and event-driven investing. The company's investment case now rests on three things: a portfolio of roughly A$3m, A$3.8m of cash at June 2026, and the conversion of legacy legal claims into cash. In mid-2026 the company received A$2.6m in settlements, which lifted NTA to about 34 cents.
Company's own description (paraphrased from the FY2023 Annual Report and FY2026 Appendix 4E). BHD describes itself as a listed investment company that gives investors exposure to an actively managed portfolio. The portfolio holds a small number of high-conviction investments in undervalued assets, aiming for above-average returns while limiting volatility over the medium to long term. Its stated investment objective is moderate to high portfolio returns over the medium to long term. The company characterises its style as "opportunistic", targeting an absolute return. The monthly NTA reports list the four primary strategies:
Discount capture: buying LICs that trade at large discounts to NTA.
Arbitrage: typically later-stage takeover situations, sometimes with short positions used to hedge market exposure.
Deep value: overlooked or out-of-favour securities where a re-rating is expected.
Event-driven: positions taken ahead of an anticipated catalyst.
Business model. BHD is a closed-end investment company. It raises permanent equity capital once, invests it, and generates returns through:
-
realised and unrealised gains on investments;
-
dividend and distribution income;
-
interest on cash;
-
since 2026, litigation recoveries.
It charges no fees to third parties and has no customers in the commercial sense. Its "product" is its own shares, which give exposure to the portfolio. Since the June 2019 board change there has been no external investment manager and no management or performance fee. Running costs are directors' fees (A$308,000 in FY2026), professional and legal fees (A$685,687 in FY2026) and minor administration costs.
Revenue model mix (FY2026; source: FY2026 Appendix 4E, Note 5).
Percentages do not sum to 100 because the realised and unrealised lines offset each other. In product, service, subscription or licensing terms, 100% of income is investment income. There is no product, service, subscription or licensing revenue.
Value-chain position. BHD is an end investor (asset owner) at the bottom of the capital-markets value chain. Its counterparties are:
-
stockbrokers, for execution;
-
the share registry (MUFG Corporate Markets);
-
the auditor (Pitcher Partners);
-
legal advisers, who are a major cost centre;
-
the investee companies and funds themselves.
"Customer" types. The shareholder base is concentrated and retail- and SMSF-heavy. At 18 August 2023 there were 345 holders, the top 20 held 75.45%, and 76 holders had less than a marketable parcel (FY2023 Annual Report). Strategic and activist holders include:
-
Glennon Small Companies Ltd / Glennon Capital, about 21.4%;
-
Keybridge Capital Ltd, about 15.4%;
-
director Sulieman Ravell's interests, about 11.3%.
End-markets. Australian listed equities, listed property trusts and REITs, closed-end private-equity feeder funds and other LICs. The company reports operating in a single geographic segment (Australia), although some investee vehicles hold offshore assets. The Cordish Dixon private-equity funds, for example, invest in US private markets.
Independent characterisation. In substance BHD is a post-crisis "recovery LIC". Its economic value has three parts:
-
a modest, liquid, deep-value equity portfolio of about A$2.9m at June 2026;
-
a large cash balance (A$3.78m at June 2026, about 56% of total assets), held partly to fund litigation;
-
a set of legal claims arising from the 2017–2018 related-party transactions with the JBL group.
Those claims had a contractual face value of about A$8.6m and were fully impaired. In June–August 2026 the board crystallised A$2.6m of recoveries. It also obtained an A$8.97m default judgment against JB Markets Pty Ltd, to which it ascribes no value. The cost base (about A$1.0m in FY2026 including legal fees) is very high relative to net assets of A$5.7m. The next phase is therefore likely to turn on capital management, whether that is a return of capital, a buy-back, a merger with a related LIC or a wind-up, rather than on portfolio performance alone. This is an analyst inference. The board's only stated intention so far is to explore capital management options (Kalkine summary of the 20 July 2026 Litigation Update).
Strategy
Stated strategic themes (paraphrased from the FY2023 Annual Report and 2026 NTA reports):
-
Capital preservation first. The board deploys capital gradually and holds high cash levels, historically 25–30% and about 56% of total assets at June 2026, partly to fund the pursuit of loan recoveries.
-
Wide, flexible mandate. It uses four opportunistic strategies (discount capture, arbitrage, deep value, event-driven) and targets absolute returns.
-
Maximising return of capital from investments. The FY2023 report says the company will continue as an LIC focused on achieving the maximum return of capital from its investments.
-
Recovery of legacy assets. The board pursues the claims it judges most likely to succeed and produce cash. It has warned shareholders that litigation costs would weigh on NTA in the interim.
Medium-term financial targets and guidance. None published. BHD gives no earnings guidance, NTA targets or cost-reduction targets. Sustainability and ESG commitments: none disclosed. The company states it is not subject to significant environmental regulation.
Products & Services
BHD has no products, brands, platforms or services for sale. The closest equivalents are:
-
the listed security itself (BHD ordinary shares), which is the "product" sold to investors;
-
its four investment strategies;
-
its disclosed portfolio holdings, which are its working capital.
These are catalogued below so the full exposure is visible.
5.1 The listed security
5.2 Investment strategies
5.3 Disclosed significant holdings (31 July 2026; source: NTA announcement, 14 August 2026)
The company notes that other large holdings may remain undisclosed.
5.4 Historical full holdings list (30 June 2023; source: FY2023 Annual Report, supplementary information)
5.5 Legacy claims portfolio (contingent assets; source: FY2026 Appendix 4E, Note 18)
Product Portfolio
| Attribute | Detail (source: FY2026 Appendix 4E) |
|---|---|
Instrument | Fully paid ordinary shares, ASX: BHD |
Shares on issue | 24,155,241 |
Options / convertibles on issue | Nil |
Dividend status | No dividends paid in FY2022–FY2026. Profit reserve of A$1,496,543 "preserved for future dividend payments"; franking credits of A$510,016 available |
Fees | No external management fee or performance fee since 2019 |
Pricing | Exchange-traded. Historically at a large discount to NTA (A$0.18 price vs about A$0.24 NTA at 30 June 2026, about a 25% discount) |
| Strategy | Description (paraphrased from the 14 August 2026 NTA report) | Example exposure |
|---|---|---|
Discount capture | Buy LICs and closed-end funds trading at wide discounts to NTA | Cordish Dixon Private Equity Funds I, II, III |
Arbitrage | Late-stage takeover targets; may short to hedge | Not individually disclosed |
Deep value | Overlooked securities expected to re-rate | Navigator Global Investments, HealthCo Healthcare & Wellness REIT, Humm Group, Kyron Capital Group |
Event-driven | Positions ahead of an anticipated catalyst | Not individually disclosed |
| Holding | Allocation (% of portfolio) | Strategy | Rationale (paraphrased) |
|---|---|---|---|
Cordish Dixon Private Equity Funds I, II, III | 18.06 | Deep value / discount capture | Maturing US private-equity funds of funds, bought at large discounts to NTA and now distributing capital |
Navigator Global Investments (ASX: NGI) | 7.80 | Deep value | Holds strategic stakes in diversified alternative asset managers |
HealthCo Healthcare & Wellness REIT (ASX: HCW) | 6.10 | Deep value | Hospital and health property REIT trading at a deep discount to NTA because of uncertainty over major tenant Healthscope; board believes most downside is priced in |
Kyron Capital Group (formerly Elanor Investors Group) | 3.11 | Deep value | Property funds manager re-quoted in June 2026 after nearly two years of suspension following 2024 covenant breaches; board sees it as undervalued relative to about A$1.85bn of funds under management |
Humm Group Ltd (ASX: HUM) | 2.93 | Deep value | Profitable non-bank lender trading below book value |
| Holding | Market value at 30 June 2023 (AUD) |
|---|---|
Kiland Ltd | 574,100 |
CD Private Equity Fund II | 560,292 |
Unibail-Rodamco-Westfield | 513,975 |
CD Private Equity Fund III | 483,660 |
Elanor Investors Group | 337,361 |
Link Administration Holdings | 264,555 |
Humm Group | 228,340 |
Sequoia Financial Group | 209,214 |
Navigator Global Ltd | 177,322 |
CD Private Equity Fund I | 135,637 |
Bailador Technology Investments | 133,975 |
Carindale Property Trust | 133,163 |
Aurizon Holdings | 120,513 |
Iperionx Ltd | 111,500 |
Platinum Asset Management | 95,700 |
1851 Emerging Companies Fund (other investment) | 87,678 |
Kogan.com | 83,473 |
Qoria Ltd | 79,875 |
NAOS Ex-50 convertible bond | 56,700 |
Elanor Retail Property Fund | 29,040 |
Total investments | 4,416,074 |
| Claim | Contractual amount at 30 June 2026 (AUD) | 30 June 2025 (AUD) | Carrying value |
|---|---|---|---|
JBFG convertible loan plus interest | 4,936,311 | 4,483,950 | Nil |
JBL loan plus interest | 2,058,695 | 1,836,057 | Nil |
JBFG loan plus interest | 1,630,532 | 1,490,695 | Nil |
Overpaid performance fee | 53,773 | 53,773 | Nil |
Default judgment against JB Markets (6 August 2026) | 8,971,570 | — | Nil (no value attributed) |
Financial Narrative
Sources.
-
FY2022 and FY2023: FY2023 Annual Report (audited).
-
FY2025 and FY2026: FY2026 Appendix 4E (FY2026 unaudited; FY2025 comparatives audited).
-
FY2024: net result, closing equity, closing cash and closing investments are taken from comparatives and the reconciliations in the FY2026 report. The FY2024 income statement detail and total assets were not in the sources reviewed and are left blank.
All figures are in A$ thousands unless stated.
6.1 Income statement
Notes:
-
FY2024 EPS is derived as the A$566,926 loss divided by 24,155,241 shares.
-
The FY2026 commentary text gives the FY2025 loss as A$709,147 while the tables show A$709,247. The A$709,247 figure is used here; the A$100 difference appears to be a typographical error.
-
Gross profit, operating income and EBITDA are not meaningful for an LIC with no cost of sales, depreciation or debt. For BHD, operating income is effectively the pre-tax result, and EBITDA equals the pre-tax result less interest income.
6.2 Margins and growth
Notes:
-
The FY2022 net margin is not meaningful because total income was negative.
-
Revenue CAGR is not meaningful: total income was negative in FY2022 and is missing for FY2024. From FY2023 to FY2026, total income fell from A$905.8k to A$619.1k, a compound change of about -11.9% a year. This mainly reflects the end of interest accruals on impaired loans.
6.3 Balance sheet (30 June)
Notes:
-
Working capital equals net assets because the balance sheet is presented on a liquidity basis with no non-current liabilities.
-
Book value per share is equity divided by 24,155,241 shares.
6.4 Cash flow
Notes:
-
As is usual for an LIC, investment purchases and sales are classified as operating cash flows.
-
FY2024 operating cash flow is derived from the change in cash (A$3,540,210 less A$3,287,667), because investing and financing flows were nil in every year reviewed.
-
Free cash flow equals operating cash flow because there is no capex.
6.5 Ratios
Notes:
-
The company's return figures come from the FY2023 Annual Report and FY2026 Appendix 4E. The small FY2022 difference against the computed ROE (-17% vs -15.6%) probably reflects a different denominator definition.
-
ROIC equals ROE because there is no debt. Net debt/EBITDA and interest coverage are not applicable (no debt and no interest expense). The cash conversion cycle is not applicable (no inventory or trade receivables).
-
The FY2026 jump in payables to A$1,056,538 (from A$423,878) is the main reason the liquidity ratio fell. It most likely reflects accrued legal fees ahead of the July 2026 final hearing. This is an inference; the composition is not disclosed.
6.6 Commentary on trends, inflections and drivers
Shrinking capital base: Net assets fell in four of the five years, from A$8.55m at 1 July 2021 to A$5.71m at 30 June 2026, a 33% decline. With no capital raisings, dividends or buy-backs, this is almost entirely the cumulative effect of losses. Cumulative losses over FY2022–FY2026 were A$2.85m, of which FY2022 (A$1.24m) was the worst year.
Cost drag: The fixed cost base has become the dominant driver of returns:
-
directors' fees have been roughly flat at about A$303k–308k;
-
professional fees, mostly legal, rose from A$187,775 in FY2023 to A$524,585 in FY2025 and A$685,687 in FY2026.
Total expenses equalled about 17.6% of average equity in FY2026. A portfolio of about A$3m invested in risk assets cannot plausibly earn that back. This is why the litigation outcome dominates the investment case.
Portfolio returns: - The investment portfolio itself has been reasonably resilient. The board reported a gross portfolio return of 9.83% in FY2023, against 14.7% for the S&P/ASX 200 Accumulation Index and 8.45% for the Small Ordinaries Accumulation Index. In FY2022 it reported -5.97%, against -6.47% for the ASX 200 and -19.5% for the Small Ordinaries (FY2022 Financial Report). This was achieved with 25–30% held in cash.
-
FY2026 was positive at the portfolio level, with a net gain of A$534,741 from the investment portfolio. The overall loss came from costs.
-
The FY2026 Remuneration Report states that the portfolio underperformed the ASX 200 Accumulation Index.
Accounting quirk in FY2022–FY2023 income: Reported interest income of A$560k–665k included contractual interest accrued on defaulted JBL-group loans, which was simultaneously impaired. The FY2023 detail shows A$338,957 of convertible-loan interest and A$264,717 of other loan interest, all fully provided for. From FY2025 the company stopped recognising this interest in profit and loss. That explains the step-down in reported interest income to about A$84k, which is now genuine cash interest.
Post-balance-date inflection: The A$2.6m of settlement cash received in July–August 2026 is not in the FY2026 accounts. It is roughly equal to 46% of 30 June 2026 equity. On a simple pro forma basis it lifts NTA to about A$8.3m, or about 34.4 cents per share, before any related legal costs. This is consistent with the reported 31 July 2026 NTA of 34.10 cents.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment and Revenue by Segment (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Segment total income (AUD K) | -171.3 | 905.8 | — | 183.0 | 619.1 |
Segment pre-tax result (AUD K) | -1,239.0 | 87.4 | -566.9 | -709.2 | -420.9 |
Segment share of total income (%) | 100 | 100 | 100 | 100 | 100 |
Function Details
| Function | Responsible party |
|---|---|
Portfolio management | Board, led by Chair Michael Glennon (career small-cap portfolio manager) |
Company secretarial | Michael Glennon |
Audit & Risk Committee | Full board; chaired by Gary Miller |
Remuneration Committee | Chaired by Gary Miller; held no meetings in FY2023 |
Litigation oversight | Board, with external solicitors |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Net gain/(loss) from investment portfolio (AUD K) | -870.5 | 240.3 | — | 98.5 | 534.7 |
Dividend income (AUD K) | 146.4 | 114.9 | — | 38.0 | 24.7 |
Other income from investments (AUD K) | 270.3 | 375.1 | — | 410.8 | 616.8 |
Net realised gain/(loss) on investments (AUD K) | 536.6 | -485.3 | — | -141.0 | 518.1 |
Interest income (AUD K) | 560.0 | 665.3 | — | 84.5 | 84.4 |
Other revenue / cost recoveries (AUD K) | 139.3 | 0.3 | — | 0 | 0 |
Total income (AUD K) | -171.3 | 905.8 | — | 183.0 | 619.1 |
Total expenses (AUD K) | 1,067.8 | 818.4 | — | 892.2 | 1,040.1 |
Directors' fees (AUD K) | 302.5 | 303.9 | — | 306.6 | 308.0 |
Professional fees (AUD K) | 266.8 | 187.8 | — | 524.6 | 685.7 |
Impairment of receivables (AUD K) | 446.5 | 264.7 | — | 0 | 0 |
Pre-tax profit (AUD K) | -1,239.0 | 87.4 | -566.9 | -709.2 | -420.9 |
Income tax (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net profit (AUD K) | -1,239.0 | 87.4 | -566.9 | -709.2 | -420.9 |
EPS basic (cents) | -5.13 | 0.36 | -2.35 | -2.94 | -1.74 |
EPS diluted (cents) | -5.13 | 0.36 | -2.35 | -2.94 | -1.74 |
Dividends per share (cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2025 | FY2026 |
|---|---|---|---|---|
Net margin on total income (%) | — | 9.6 | -387.6 | -68.0 |
Expenses / average equity (%) | 13.5 | 11.1 | 13.8 | 17.6 |
Expenses ex-impairment / average equity (%) | 7.8 | 7.5 | 13.8 | 17.6 |
Total income growth YoY (%) | — | — | — | 238.3 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD K) | 7,710.6 | 7,738.5 | — | 6,550.6 | 6,762.4 |
Cash and equivalents (AUD K) | 1,334.9 | 3,287.7 | 3,540.2 | 3,153.0 | 3,778.2 |
Investments at fair value (AUD K) | 6,115.5 | 4,416.1 | 3,726.2 | 3,370.6 | 2,940.3 |
Other receivables (AUD K) | 225.7 | 9.7 | — | 2.0 | 18.8 |
Total liabilities, all trade payables (AUD K) | 395.1 | 335.6 | — | 423.9 | 1,056.5 |
Short-term debt (AUD K) | 0 | 0 | 0 | 0 | 0 |
Long-term debt (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net debt, negative = net cash (AUD K) | -1,334.9 | -3,287.7 | -3,540.2 | -3,153.0 | -3,778.2 |
Total equity (AUD K) | 7,315.6 | 7,402.9 | 6,836.0 | 6,126.8 | 5,705.8 |
Goodwill and intangibles (AUD K) | 0 | 0 | 0 | 0 | 0 |
Working capital (AUD K) | 7,315.6 | 7,402.9 | 6,836.0 | 6,126.8 | 5,705.8 |
Book value per share (cents) | 30.3 | 30.6 | 28.3 | 25.4 | 23.6 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD K) | -676.0 | 1,952.8 | 252.5 | -387.2 | 625.1 |
Payments for investments (AUD K) | -7,201.1 | -3,027.5 | — | -2,406.7 | -1,985.2 |
Proceeds from sale of investments (AUD K) | 6,721.4 | 4,866.0 | — | 2,418.4 | 2,345.5 |
Capex (AUD K) | 0 | 0 | 0 | 0 | 0 |
Free cash flow (AUD K) | -676.0 | 1,952.8 | 252.5 | -387.2 | 625.1 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%) | -15.6 | 1.2 | -8.0 | -10.9 | -7.1 |
Company-reported return on average capital employed (%) | -17 | 1 | — | -11 | -7 |
ROA on closing assets (%) | -16.1 | 1.1 | — | -10.8 | -6.2 |
Liquidity ratio: total assets / liabilities (x) | 19.5 | 23.1 | — | 15.5 | 6.4 |
Debt to equity (x) | 0 | 0 | 0 | 0 | 0 |
Cash / total assets (%) | 17.3 | 42.5 | — | 48.1 | 55.9 |
Asset turnover: total income / closing assets (x) | — | 0.12 | — | 0.03 | 0.09 |
Revenue by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia (AUD K) | — | 183.0 | 619.1 |
Offshore (AUD K) | 0 | 0 | 0 |
Capital Markets Data (AUD) and Per-Share Data
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
Share price at 30 June (AUD) | 0.71 | 0.21 | 0.31 | 0.22 | 0.22 | 0.22 | 0.18 | 0.18 |
Reported NTA before deferred tax (AUD) | 0.33 | 0.30 | 0.35 | 0.30 | 0.31 | — | 0.25 | 0.24 |
Book value per share, computed (AUD) | — | — | 0.354 | 0.303 | 0.306 | 0.283 | 0.254 | 0.236 |
Price discount to book value (%) | — | — | 12.4 | 27.4 | 28.1 | 22.3 | 29.1 | 23.7 |
Net profit (AUD K) | -9,821.5 | -750.2 | 1,260.8 | -1,239.0 | 87.4 | -566.9 | -709.2 | -420.9 |
Month-end Details
| Month-end | NTA (cents) | Monthly gross portfolio return |
|---|---|---|
Dec 2024 | 25.94 | — |
Jan 2025 | 26.44 | +2.38% |
Jun 2025 | 25.52 | +1.60% |
Dec 2025 | 26.68 | +0.92% |
Jan 2026 | 27.31 | +3.85% |
Feb 2026 | 26.11 | -3.32% |
Apr 2026 | 25.36 | +1.92% |
Jul 2026 | 34.10 | +1.40% (includes settlements) |
Share Price History
| Period | Start price (AUD) | End price (AUD) | Change |
|---|---|---|---|
1 year (about Oct 2025 to Oct 2026) | about 0.185 | 0.255 | about +38% |
3 years (30 Jun 2023 to latest) | 0.22 | 0.255 | about +16% |
5 years (30 Jun 2021 to latest) | 0.31 | 0.255 | about -18% |
Valuation Snapshot
| Multiple | Value | Comment |
|---|---|---|
EV/Sales (total income) | About 3.9x | A$2.38m ÷ A$0.619m; low relevance for an LIC |
P/B (30 June 2026 book) | About 1.08x | A$0.255 ÷ A$0.236 |
Price / latest NTA (31 Jul 2026) | About 0.75x (about a 25% discount) | A$0.255 ÷ A$0.341 |
Price / NTA including deferred tax assets | About 0.55x | A$0.255 ÷ (A$0.341 + about A$0.12) |
Capital Markets
| Item | Detail |
|---|---|
Analyst consensus | None. BHD is not covered by a major broker (Market Index) |
Dividend history | No dividends in FY2019–FY2026. Dividends and a DRP were declared under the former manager in FY2018 |
Dividend policy | No current policy; profit reserve of A$1.50m earmarked for future dividends; franking credits of A$510k |
Buy-back authorisations | None current. The FY2023 report confirms no on-market buy-back; one existed under the former manager in 2018 |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | No debt |
Liquidity | Average daily volume about 24,000–72,000 shares across TipRanks snapshots in 2025; 345 holders at Aug 2023 |
Analyst Conclusions
Management guidance. No quantitative guidance is provided. Qualitatively, the board will maintain its wide, opportunistic mandate with a capital-preservation bias. It does not anticipate further recoveries from the JB Markets judgment, and it has said it will consider capital management after the settlements (NTA, 14 August 2026; Litigation Update, 20 July 2026).
Consensus expectations. None. The company has no analyst coverage.
Bull case
-
Discount closure through capital management. NTA of about 34.1 cents plus about 12 cents per share of unrecognised tax assets, against a A$0.255 share price, offers 34% upside to NTA alone. A buy-back, return of capital or wind-up would crystallise much of that gap.
-
Costs should fall structurally. With litigation largely concluded, legal fees (A$565,697 in FY2026) could drop toward pre-2024 levels of about A$46k (FY2023). That would roughly halve the cost base and turn the portfolio's positive investment income (A$534,741 in FY2026) into a reported profit.
-
Portfolio catalysts. Maturing Cordish Dixon funds bought at discounts (18% of the portfolio), HealthCo REIT and Kyron Capital re-ratings, and higher interest income on about A$6.4m of pro forma cash could lift NTA independently of the litigation.
Bear case
-
Fixed costs keep eroding value. Even without legal costs, directors' fees of A$308k (including additional "recovery" fees that may persist) equal about 3.7% of pro forma NTA a year. Equity has already fallen 33% since 1 July 2021.
-
Contested register and governance risk. Insiders and related LICs control over half of the register, and Keybridge holds a further 15%. Disagreement over capital management could trigger further costly contests, as seen in the 2025 Takeovers Panel matters and the remuneration strikes.
-
The discount may persist. BHD has traded 22–29% below book value at every year-end since FY2022, despite stable NTA. Without a binding capital return, illiquidity and nano-cap status may keep it there.
Key catalysts and monitorables for the next 12 months
-
Audited FY2026 Annual Report: confirm the settlement accounting, the fee arrangements and any going-concern commentary.
-
2026 AGM: Remuneration Report vote (strike history), director re-elections, any capital-management resolutions.
-
Announcement of a buy-back, return of capital, special dividend or corporate transaction.
-
Monthly NTA trend: does NTA hold about 34 cents once settlement-related legal accruals are paid?
-
Whether Miller and Ravell's additional fees cease now that recoveries have occurred.
-
Progress of the McAuliffe and Elderfield criminal trial in the Queensland District Court.
-
Register changes: identity of the July 2026 substantial holder; the actions of Keybridge and GC1.
-
Cordish Dixon distributions and outcomes for HealthCo and Kyron.
Analyst verdict. Benjamin Hornigold Ltd is best understood not as an operating investment franchise but as a balance-sheet situation that has reached its endgame. The 2017–2018 related-party transactions with John Bridgeman Ltd destroyed most of the original capital: issued capital is A$23.5m against net assets of A$5.7m at June 2026. They also left the company with impaired claims, a governance stigma and a register shaped by activists. The 2019 board has done the essential work. It stabilised the portfolio, kept a large cash buffer, avoided external fees and, in mid-2026, converted years of litigation into A$2.6m of cash, lifting NTA to about 34 cents per share.
The economics remain fragile, however. FY2026 showed a portfolio that made money (A$534,741 of net investment income) inside a company that lost money (A$420,931), because costs ran at about 17.6% of equity. With the litigation essentially exhausted, the case for continuing as a standalone A$8m LIC is weak on cost grounds alone. The rational value-maximising paths are capital return, buy-back, merger with a related vehicle or orderly wind-up. Any of these would tend to close a discount of about 25% to NTA, and a merger could also extract value from about A$3.1m of tax-effected losses.
The main risks are inertia, meaning the board keeps the vehicle running with a fixed cost base that steadily erodes NTA, and conflict among the concentrated holders. These include the Chair's own GC1 vehicle, director Ravell and Keybridge.
On balance, BHD offers asymmetric, event-dependent value for patient holders of a highly illiquid security. The investment outcome depends almost entirely on board decisions over the next two to three reporting periods, not on markets. The audited FY2026 Annual Report and the 2026 AGM are the decisive near-term tests.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Qualifications | Background | Other listed directorships |
|---|---|---|---|---|---|
Michael Glennon | Non-Executive Chairman; Company Secretary | 12 Jun 2019 | Bachelor of Commerce | CIO and Portfolio Manager at Glennon Capital Pty Ltd; small-cap portfolio manager since 1999; co-founder of several boutique funds-management firms | Glennon Small Companies Ltd (ASX: GC1) since 29 Apr 2015; formerly Excelsior Capital Ltd (ASX: ECL), resigned 4 Oct 2019 |
Gary Miller | Non-Executive Director; Chair of Audit & Risk and Remuneration Committees | 12 Jun 2019 | Diploma of Financial Advising | About 30 years in financial markets; director (2011–April 2020) and Responsible Officer of Miller Wealth Management Pty Ltd (AFSL holder 2011–2020); former partner in a Brisbane financial-planning firm; former investment committee member of an ASX-listed financial services group; commercial property and development finance experience | — |
Sulieman Ravell | Non-Executive Director | 12 Jun 2019 | BEng (Hons), AFPC (UK), ADFP, Cert IV Mortgage Services | 25+ years in financial services; Representative Director and Responsible Manager of NW Advice Pty Ltd and Wealth Focus Pty Ltd; former member of the Filtered Research Committee | Glennon Small Companies Ltd (ASX: GC1) since 9 Jun 2020 |
Directors' Remuneration
| Director | FY2026 fees | FY2026 superannuation | FY2026 total | FY2025 total |
|---|---|---|---|---|
M Glennon | 75,000 | 9,000 | 84,000 | 83,625 |
G Miller | 100,000 | 12,000 | 112,000 | 111,500 |
S Ravell | 100,000 | 12,000 | 112,000 | 111,500 |
Total | 275,000 | 33,000 | 308,000 | 306,625 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
Jun 2019 | Entire prior board, including CEO Stuart McAuliffe, resigns; Glennon, Miller and Ravell appointed | Governance crisis after related-party payments to JBL and the 2018 suspension |
Since Jun 2019 | No changes | Board stable for over seven years |
Major Shareholders
| Holder | Shares | % | Date / source |
|---|---|---|---|
J P Morgan Nominees Australia Pty Ltd (nominee) | 5,429,880 | 22.48 | Market Index |
Glennon Capital Pty Ltd (via Glennon Small Companies Ltd, GC1); linked to Chair Michael Glennon | 5,170,174 | 21.40 | InvestSMART substantial holders; FY2026 Remuneration Report |
Keybridge Capital Ltd | 3,727,067 | 15.43 | Market Index; InvestSMART |
Sulieman Ravell interests (S4 Super, S4 Family Trust, Wealth Focus) | 2,732,174 | 11.31 | FY2026 Remuneration Report |
Dawney & Co Ltd | 2,907,892 | 12.04 | — |
Hurlbook Pty Ltd (Skitt Family Super Fund) | 1,385,000 | 5.73 | FY2023 top 20 |
GTM Family Super Pty Ltd (Gary Miller) | 1,207,130 | 5.00 | FY2026 Remuneration Report |
John Charles Plummer and associates | 1,239,807 | 5.13 | FY2023 substantial holders |
Barracuda Capital Pty Ltd | 922,565 | 3.82 | FY2023 top 20 |
Co Super Pty Ltd (Rojek Super Fund) | 489,690 | 2.03 | FY2023 top 20 |
Competitive Landscape
Key Competitors
| Peer (ASX code) | Relevance to BHD | Relative positioning |
|---|---|---|
Glennon Small Companies Ltd (GC1) | Same Chair and portfolio-management lineage; 21.4% BHD holder | Related party rather than an arm's-length competitor; small-cap growth mandate |
Keybridge Capital Ltd (KBC) | 15.4% BHD holder; also a legacy-asset, deep-value vehicle; entered administration in early 2025 | Activist counterparty; contested control history |
WAM Capital and other Wilson Asset Management LICs (WAM family) | Linked to the Keybridge requisition; dominant player in LIC discount-capture and market-driven strategies | Far larger scale and brand; sets the competitive benchmark for discount capture |
Sandon Capital Investments (SNC) | Activist, event-driven micro/small-cap LIC | — |
Thorney Opportunities (TOP) | Deep-value, event-driven micro-cap LIC | Similar style; listing status to be verified |
Ryder Capital (RYD) | Concentrated, absolute-return small-cap LIC | — |
NAOS Emerging Opportunities (NCC) and related NAOS LICs | Concentrated small and micro-cap; BHD held a NAOS Ex-50 convertible bond in 2023 | Status after any sector consolidation to be verified |
Flagship Investments (FSI) | Small, long-running ASX LIC | Comparable micro-scale vehicle |
Acorn Capital Investment Fund (ACQ) | Listed and unlisted micro-cap fund | Comparable hybrid of listed and unlisted exposure |
Bailador Technology Investments (BTI) | Listed vehicle for unlisted growth investments; held by BHD in 2023 | Example of a discounted closed-end vehicle BHD targets |
Peer Comparison FY2026
| Metric | BHD (FY2026) | Peer 1 | Peer 2 | Peer 3 |
|---|---|---|---|---|
Net assets | A$5.71m | — | — | — |
Total income growth | +238% | — | — | — |
Net margin on income | -68% | — | — | — |
Expense / average equity | 17.6% | — | — | — |
R&D intensity | 0% (not applicable) | 0% | 0% | 0% |
Management fee | Nil (self-managed) | — | — | — |
Recent Developments
No layoffs, hiring, guidance revisions or regulatory actions against the company itself occurred in the period. The ASIC actions concern former officers and JBL-group entities.



